What is DRTS's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for DRTS.

Stock Ratings / Health Care / DRTS / options

BVS (61) AORT (40) PRCT (38) TNDM (28) ⌘ Pro Terminal →

Alpha Tau Medical Ltd. (DRTS) Options Positioning, Max Pain & Unusual Sweeps

$12.83 -1.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.76

Alpha Tau Medical Ltd. (DRTS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.21B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DRTS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DRTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Alpha Tau Medical Ltd. (NASDAQ: DRTS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $12.83 (-1.76% 1D, market cap $1.21B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DRTS ranks #502 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DRTS compare to BVS and AORT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), DRTS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BVS (Bioventus Inc. (Class A)) holds a C- grade (61/100 RQD, P/E 55.0x, ROIC 10.4%, cap $1.12B) and AORT (Artivion Inc.) posts a D- grade (40/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.10B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DRTS?

▼

Per DRTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001871321), Alpha Tau Medical Ltd. generated $118.4M in revenue (+17.3% YoY), -$42.6M in net income, and -$32.8M in free cash flow against $105.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.76 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRTS)Realized 20D OHLCV Swing Band: ±9.2%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY DRTS SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 76% of 52W Range • RSI-14 at 43.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$13.74-4.7% Next Q

Q2 (-2Q)

Grade D$13.09+3.2% Next Q

Q3 (-1Q)

Grade D$13.51-5% Next Q

Current

Grade D-$12.83-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DRTS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DRTS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.19) and Max Pain ($13.47) forces dealer call-delta covering toward $16.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DRTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DRTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.2%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (DRTS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for DRTS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRTS)

✓Walkthrough of DRTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DRTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +70.39%🛡️ HOLDING TREND SUPPORT

2026-11-03O $13.23H $13.23L $12.83C $12.83VOL 475.4K

RES: $17.28SUP: $12.21SMA50: $14.19SMA200: $10.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRTS Butterfly Map → + Track DRTS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DRTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DRTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRTS)

Health Care Rank #502 of 1015 ⚔️ BVS vs DRTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRTS vs. BVS, AORT, PRCT, TNDM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Alpha Tau Medical Ltd. (DRTS) ranks #502 by composite RQD confidence (38/100, grade D-) and #332 by equity capitalization ($1.21B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with DRTS at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DRTS ACTIVE Alpha Tau Medical Ltd.	D-	38/100	—	—	-35.0%	-1.76%	$1.21B	Benchmark Subject
BVS Bioventus Inc. (Class A)	C-	61/100	55.0x	68.3%	10.4%	-1.31%	$1.12B	/bvs-vs-drts →
AORT Artivion Inc.	D-	40/100	117.0x	64.4%	4.5%	+4.43%	$1.10B	/aort-vs-drts →
PRCT PROCEPT BioRobotics Corporation	D-	38/100	—	63.7%	-35.0%	+1.25%	$1.10B	/prct-vs-drts →
TNDM Tandem Diabetes Care Inc.	E	28/100	—	53.8%	-35.0%	-2.30%	$1.33B	/tndm-vs-drts →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001871321 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alpha Tau Medical Ltd. (DRTS) reported GAAP revenue of $118.4M (+17.3% vs. FY2024 revenue of $100.9M , and +18.5% cumulative change since FY2023) , GAAP net income of -$42.6M, operating cash flow of -$26.7M, and free cash flow of -$32.8M (-48.7% YoY). On the balance sheet, DRTS closed FY2025 with $105.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$118.4M	-$42.6M	-$26.7M	-$32.8M	$105.7M	—
FY2024 (FY)	2024-12-31	$100.9M	-$31.8M	-$19.8M	-$22.0M	$86.2M	—
FY2023 (FY)	2023-12-31	$99.9M	-$29.2M	-$18.0M	-$18.0M	—	—

3. DRTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DRTS compare to BVS and AORT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DRTS?

Where is DRTS trading relative to its 50-day, 200-day, and 52-week technical levels?

DRTS last traded at $12.83 (-1.76% on volume of 436,875 shares), positioning the stock -9.58% below its 50-day simple moving average ($14.19) and +20.47% above its 200-day simple moving average ($10.65). Across its 52-week range of $3.43 to $15.79, DRTS sits at the 76.1% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($11.65 to $14.01).

Direct Sub-Reports: DRTS RQD Cockpit DRTS 12M Forecast DRTS Earnings & Move DRTS Dividends & DRIP DRTS Insiders & 13F DRTS Whale Options DRTS Profit Sankey DRTS News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

DRTS — Alpha Tau Medical Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Alpha Tau Medical Ltd. (DRTS) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $12.83 (-1.76% 1D, market capitalization $1.21B).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -2.68%.
Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Alpha Tau Medical Ltd. (DRTS) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry..2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Alpha Tau Medical Ltd. (DRTS) reported $118.4M in annual revenue (up from $100.9M in FY2024, +17.3% YoY) and -$42.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($99.9M revenue, -$29.2M net income) through FY2025, DRTS scaled operating cash flow to -$26.7M and free cash flow to -$32.8M, backed by $105.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.68% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $3.43 – $15.79 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations therefore cannot be mapped from the source data. The only sector context available is the classification of Health Care / Medical/Dental Instruments. A prospective investor should note that 2nd-order ripple effects, such as dependence on trial sites, partners, or regulators, are not documented in the supplied data.

Key Question #1: Can DRTS sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $118.4M and free cash flow of -$32.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is DRTS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DRTS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alpha Tau Medical Ltd. (DRTS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DRTS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 23h ago

How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer Trial

Yahoo Finance report covering Alpha Tau Medical Ltd. (DRTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial expansion

Investing.com report covering Alpha Tau Medical Ltd. (DRTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Alpha Tau Signs MOU with Samsung Medical Center for Pancreatic Cancer Trial in Korea

The Globe and Mail report covering Alpha Tau Medical Ltd. (DRTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Alpha Tau Medical Ltd Estimates – TASE:DRTS

TradingView report covering Alpha Tau Medical Ltd. (DRTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

How Expanded Glioblastoma Trial Will Impact Alpha Tau Medical Stock (DRTS)

Simply Wall St report covering Alpha Tau Medical Ltd. (DRTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

FDA allows a larger cancer trial at three U.S. centers for Alpha Tau (DRTS).

Stock Titan report covering Alpha Tau Medical Ltd. (DRTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange

GlobeNewswire report covering Alpha Tau Medical Ltd. (DRTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Alpha Tau signs MOU for potential pancreatic cancer trial | DRTS Stock News

Stock Titan report covering Alpha Tau Medical Ltd. (DRTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DRTS Bull vs. Bear Conversation Board — What's Your Call at $12.83?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DRTS 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $16.19 (+24.0%)

📌 Pinned Debate

Expanded FDA-allowed trials across three U.S. centers and a Samsung Medical Center MOU offer clinical catalysts that could support the

Here is why I am bullish on DRTS here at $13.06: Expanded FDA-allowed trials across three U.S. centers and a Samsung Medical Center MOU offer clinical catalysts that could support the valuation if they convert to commercial progress.. Compare DRTS's 0.0% operating margin and -35.0% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $12.41 are getting bought.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $10.58 (-19.0%)

Spot @ $13.06

With zero reported revenue, ROIC of -35%, FCF yield of -2.68%, and cash falling to $12.2M against -$42.6M net loss, the company faces c

Careful chasing DRTS at $13.06. With zero reported revenue, ROIC of -35%, FCF yield of -2.68%, and cash falling to $12.2M against -$42.6M net loss, the company faces cash-burn pressure that the market cap of $1.22B may not reflect.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $10.58 on multiple compression.